Clinical trial
Personalization of Long-Term Antiplatelet Therapy Using a Novel Combined Demographic/Pharmacogenomic Strategy - The RAPID EXTEND Randomized Study
NCT03729401 is registered in ClinicalTrials.gov with Ottawa Heart Institute Research Corporation as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Personalization of Long-Term Antiplatelet Therapy Using a Novel Combined Demographic/Pharmacogenomic Strategy - The RAPID EXTEND Randomized Study
- Lead sponsor
- Ottawa Heart Institute Research Corporation
- Phase
- Phase 4
- Overall status
- Terminated
- Start date
- August 22, 2019
- Completion date
- February 26, 2026
- Enrollment
- 39 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.